Drug Trial Radar · NCT06321562
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Mar 1, 2023
Primary completion
Jun 26, 2025
Study completion Jun 26, 2025
Sponsor
- Lead sponsor
- EyeD PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia (currently present or to be performed during the concomitant implantation surgery in subjects with age-related cataract eligible to intra-capsular IOL placement). The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it. The study will also check: * how safely the implant is placed in and removed from the eye and how the body responds to the procedure, * how safe different doses of timolol are and how the body handles taking it, * the amount of Timolol released in the bloodstream, * if there is any positive effect on the pressure inside the eye.
Conditions
- Primary Open-angle Glaucoma
Interventions
TimoD implantDrug
Consists of 1 TimoD implant administration in the study eye
Injector systemDevice
This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and proportion of participants experiencing one or more serious adverse events (SAEs)Time frame: From screening visit (up to Day -41) to end of study (Week 108)
- Number and proportion of participants experiencing one or more treatment-emergent adverse events (TEAEs) overall and by dose groupTime frame: From screening visit (up to Day -41) to end of study (Week 108)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Breyer, Kaymak & Klabe Augenchirurgie
Düsseldorf, Germany
Universitäts-Augenklinik Heidelberg
Heidelberg, Germany
Universitätsaugenklinik Magdeburg
Magdeburg, Germany
Augenklinik Sulzbach
Sulzbach, Germany
Universitäts-Augenklinik Tübingen
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.